Can Roche Follow Biogen With Success In Alzheimer’s?
Results Expected In November
Executive Summary
Analysts still think gantenerumab’s Phase III chances are slim, and it will have to come close to the efficacy reached by Eisai/Biogen’s lecanemab to stay in the Alzheimer’s game. The data are due out next month.